Floatz logo

mgd024

Chronic Myeloid Leukemia

MacroGenicsPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

85 Active assets in the Chronic Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
Romidepsin
Center for International Blood and Marrow Transplant Research
Phase 2BBB

View all 50 →

Same molecule, other indications

mgd024 is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
lymphoid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
hairy cell leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →